China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has struck a partnership with Indonesian firm Biotis concerning a dual carrier 13-valent pneumococcal polysaccharide conjugate vaccine. This collaboration aims to enhance vaccine accessibility and public health initiatives in Indonesia.
Agreement Details and Technical Collaboration
As per the agreement, Kangtai Bio will supply Biotis with vaccine stock solution and transfer its techniques for vaccine preparation, packaging, and final product testing. This partnership will facilitate the local manufacturing, regulatory filing, and commercial operation of the 13-valent pneumonia vaccine in Indonesia, where it is part of the national immunization plan. The financial details of the agreement have not been disclosed.
Enhancing Public Health in Indonesia
The 13-valent pneumonia vaccine, known for its ability to protect against a wide range of pneumococcal serotypes, is a crucial component of public health strategies globally. In Indonesia, its inclusion in the national immunization plan underscores the importance of preventive healthcare measures. The partnership between Kangtai Bio and Biotis is set to bolster these efforts, potentially improving the health outcomes for millions of individuals.-Fineline Info & Tech
